Table I Demographic and clinical characteristics of the studied population (n = 115)
VariableTraining set (n = 65)Validation set (n = 50)Total (n = 115)
Age (years)
    < 6029 (44.6%)27 (54.0%)56 (48.7%)
    ≥ 6036 (55.4%)23 (46.0%)59 (51.3%)
Gender
    Male58 (89.2%)44 (88.0%)102 (88.7%)
    Female7 (10.8%)6 (12.0%)13 (11.3%)
Etiology
    HBsAg-positive51 (78.5%)40 (80.0%)91 (79.1%)
    Anti-HCV-positive3 (4.6%)4 (8.0%)7 (6.1%)
    Alcohol4 (6.1%)2 (4.0%)6 (5.2%)
    Unknown7 (10.8%)4 (8.0%)11 (9.6%)
ECOG
    063 (96.9%)48 (96.0%)111 (96.5%)
    12 (3.1%)2 (4.0%)4 (3.5%)
Body mass index (kg/m2)20.5 ± 7.5622.0 ± 5.6821.1 ± 6.82
CTP classification
    A61 (93.8%)39 (78.0%)100 (87.0%)
    B4 (6.2%)11 (22.0%)15 (13.0%)
MELD score8.82 ± 1.659.81 ± 3.149.25 ± 2.45
WBC (x 103/μl)5.96 ± 2.314.74 ± 1.595.43 ± 2.11
Neutrophil (%)62.6 ± 11.561.9 ± 11.062.3 ± 11.2
Platelet (x 103/μl)175.4 ± 106.3143.0 ± 86.1161.3 ± 98.9
AFP (ng/ml)
    < 20044 (67.7%)29 (58.0%)73 (63.5%)
    ≥ 20021 (32.3%)21 (42.0%)42 (36.5%)
DCP (mAU/ml)8,301 ± 18,6513,705 ± 11,0226,825 ± 15,870
Tumor size (cm)
    < 553 (81.5%)40 (80.0%)93 (80.9%)
    ≥ 512 (18.5%)10 (20.0%)22 (19.1%)
Tumor number
    ≤ 332 (49.2%)31 (62.0%)63 (54.8%)
    4–913 (20.0%)11 (22.0%)24 (20.9%)
    ≥ 1020 (30.8%)8 (16.0%)28 (24.3%)
Vascular invasion
    No47 (72.3%)32 (64.0%)79 (68.7%)
    Yes18 (27.7%)18 (36.0%)36 (31.3%)
Lymph node
    No53 (81.5%)41 (82.0%)94 (81.7%)
    Yes12 (18.5%)9 (18.0%)21 (18.3%)
Metastasis
    No31 (47.7%)29 (58.0%)60 (52.2%)
    Yes34 (52.3%)21 (42.0%)55 (47.8%)
BCLC stage
    B (intermediate)15 (23.1%)15 (30.0%)30 (26.1%)
    C (advanced)50 (76.9%)35 (70.0%)85 (73.9%)
  • HBsAg, hepatitis B surface antigen; Anti-HCV, antibody against hepatitis C virus; ECOG, eastern cooperative oncology group; CTP, child-turcotte-pugh; MELD, model for end-stage liver disease; WBC, white blood cell; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy-prothrombin; BCLC, barcelona clinic liver cancer.